JA
JAGX.US Jaguar Animal Health Inc
- Market cap
- USD 5.59M
- P/E
- -
- P/B
- 0.84x
- ROE
- -123.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is JAGX.US undervalued?
Graham numberThe Graham number of Jaguar Animal Health Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jaguar Animal Health Inc fundamental analysis
No fundamental analysis for Jaguar Animal Health Inc yet.
Jaguar Animal Health Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jaguar Animal Health Inc
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for th…
Full company profileJaguar Animal Health Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jaguar Animal Health Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 142K | 4.36M | 4.42M | 5.78M | 9.39M | 4.34M | 12.0M | 9.76M | 11.7M | 11.5M | 43.0M |
| Gross Profit | 89.6K | 3.48M | 1.65M | 1.96M | 6.11M | 2.00M | 9.94M | 7.72M | 9.73M | 7.74M | 38.6M |
| Operating Income | -13.6M | -34.2M | -30.8M | -28.9M | -26.6M | -40.7M | -34.4M | -34.3M | -30.8M | -45.1M | 5.17M |
| EBITDA | -13.7M | -11.1M | -28.2M | -30.9M | -28.7M | -42.4M | -33.4M | -31.5M | -36.7M | -51.7M | -4.31M |
| Net Income | -14.7M | -22.0M | -32.1M | -38.5M | -33.8M | -52.6M | -47.5M | -41.3M | -38.5M | -53.4M | -8.17M |
| EPS | - | - | - | -1,284,633,333 | -153,677,273 | -69,203,947 | -28,415,569 | -1,424,138 | -68,613 | -12,027 | -151 |
| Balance Sheet | |||||||||||
| Total Assets | 3.56M | 43.6M | 41.0M | 36.4M | 42.8M | 53.3M | 47.5M | 50.8M | 53.4M | 38.3M | 34.2M |
| Total Liabilities | 6.02M | 26.4M | 35.7M | 25.7M | 25.6M | 41.4M | 48.8M | 45.9M | 46.9M | 57.0M | 29.3M |
| Shareholders' Equity | -2.45M | 17.3M | 5.38M | 10.7M | 17.2M | 11.6M | -657K | 4.96M | 7.29M | -17.3M | 6.62M |
| Cash & Short-term Investments | 951K | 521K | 2.57M | 3.50M | 8.09M | 17.1M | 5.47M | 6.47M | 8.00M | 968K | 6.59M |
| Total Debt | 3.89M | 16.4M | 16.1M | 7.57M | 16.2M | 29.4M | 34.8M | 37.1M | 36.5M | 43.6M | 16.7M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -14.4M | -9.82M | -22.7M | -20.5M | -15.3M | -35.0M | -33.1M | -33.2M | -29.4M | -23.7M | 6.98M |
| Capital Expenditure | 104K | 6.53K | 6.53K | 7.00K | 7.00K | 6.00K | 1.68M | 0.00 | 231K | 25.0K | 58.0K |
| Free Cash Flow | -14.5M | -9.82M | -22.7M | -20.5M | -15.3M | -35.0M | -34.8M | -33.2M | -29.6M | -23.7M | 6.98M |
| Ratios | |||||||||||
| ROE | - | -127.3% | -597.2% | -361.1% | -196.5% | -453.0% | - | -832.5% | -528.4% | - | -123.5% |
| ROA | -413.5% | -50.4% | -78.3% | -105.8% | -78.9% | -98.7% | -100.0% | -81.4% | -72.0% | -139.4% | -23.9% |
| Net Profit Margin | -10,410.9% | -503.7% | -727.9% | -667.3% | -360.2% | -1,213.3% | -396.9% | -423.1% | -329.3% | -464.2% | -19.0% |
| Debt to Equity | - | 0.95x | 2.99x | 0.71x | 0.94x | 2.53x | - | 7.48x | 5.01x | - | 2.52x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jaguar Animal Health Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 33.0K | 150,000 | - |
| 2019 | - | - | - |
| 2018 | USD 12.2M | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:15 on Sep 17, 2026.
Who owns Jaguar Animal Health Inc
- Insiders 0.72%
- Institutions 0.34%
- Public & others 98.95%
- Shares outstanding 13.3M
- Free float 289K
Top funds holding JAGX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 955.00 | 0.22% | -0.21% | Sep 2026 |
| Fidelity Total Market Index | 14.00 | 0.00% | -6.67% | Sep 2026 |
| Fidelity Series Total Market Index | 13.00 | 0.00% | 0.00% | Sep 2026 |
Top institutions holding JAGX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| UBS Group AG | 4.00K | 0.05% | +23.99% | Jun 2026 |
| Tower Research Capital LLC | 1.16K | 0.01% | +1,657.58% | Jun 2026 |
| SBI Securities Co Ltd | 84.00 | 0.00% | +15.07% | Jun 2026 |
| Barclays PLC | 56.00 | 0.00% | 0.00% | Jun 2026 |
| Royal Bank of Canada | 20.00 | 0.00% | 0.00% | Jun 2026 |
| Wells Fargo & Co | 5.00 | 0.00% | 0.00% | Jun 2026 |
| LEONTEQ SECURITIES AG | 5.00 | 0.00% | 0.00% | Jun 2026 |
| International Assets Investment Management, LLC | 1.00 | 0.00% | 0.00% | Jun 2026 |
| BlackRock Inc | 0.00 | 0.00% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Jaguar Animal Health Inc company profile
- Company name
- Jaguar Animal Health Inc
- Ticker
- JAGX.US
- Exchange
- USA Stocks
- Listed since
- May 13, 2015
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 47
- Fiscal year end
- December
- Address
- 200 Pine Street, San Francisco, CA, United States, 94104
- Phone
- 415 371 8300
- Website
- jaguar.health
About Jaguar Animal Health Inc
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Jaguar Animal Health Inc management
9- Ms. Lisa A. ConteFounder, CEO, President & Director · born 1959
- Dr. Pravin R. Chaturvedi Ph.D.Chief Scientific Officer & Chair of Scientific Advisory Board · born 1963
- Mr. Jonathan S. Wolin CPA, J.D., M.B.A.Chief of Staff, Chief Compliance Officer & General Counsel · born 1962
- Dr. Steven R. King Ph.D.Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Secretary · born 1958
- Ms. Carol R. Lizak M.B.A.CFO & Treasurer · born 1964
- Mr. Peter HodgeSenior Director of Investor Relations, Business Development & Special Events
- Mr. David Sesin Ph.D.Chief Manufacturing Officer
- Mr. Ian H. Wendt M.B.A.Chief Business Officer · born 1968
- Dr. Massimo Radaelli M.B.A., Ph.D.President of Jaguar International · born 1958